[AXOL] 심실심근세포 | axoCells Ventricular Cardiomyocyte | 고마바이오텍

특징

• 신약 개발의 필수 단계인 심장 독성 스크리닝(Cardiotoxicity Screening) 및 약물 검증(Drug Validation)에 최적화된 고기능성 세포 모델입니다
• 단 7일 만에 기능적으로 성숙한 심실 심근세포를 확보할 수 있습니다.
• FDA의 차세대 독성 평가 가이드라인인 CiPA(Comprehensive in vitro Proarrhythmia Assay)에 정의된 28개 화합물에 대한 테스트를 마쳤으며, 심장 독성 위험을 정확히 식별합니다.
• hERG block과 관련된 활동 전위 기간 연장(APD prolongation) 및 삼각형화(Triangulation) 현상을 정확히 감지하여, 치명적인 부정맥인 Torsades de Pointes(TdP) 유발 가능성을 사전에 예측합니다.
• 일반 배양 플레이트는 물론, Axion Maestro MEA(다전극 어레이) 시스템과 완벽하게 호환되어 심장 박동의 전기생리학적 변화를 실시간으로 모니터링할 수 있습니다.
• ISO:9001 인증 시설에서 생산되며, HPSCreg® 공식 인증 및 상세 분석 증명서(CoA)를 제공하여 윤리적·생물학적 신뢰성을 보장합니다.

적용 

• Electrophysiology : Contractility, QT prolongation, Na+ & Ca2+ channels, Pharmacology 실험
• Functional Integrity : Ca2+ signaling, Morphology, Stress & toxic response markers 확인

사양 및 제품  

* MyoMax Maturation Media 와 함께 이용 시, 심실 심근세포(Ventricular Cardiomyocytes)의 기능을 극대화 할 수 있습니다. 바로 가기 >>

Axol Human iPSC-Derived Ventricular Cardiomyocytes were cultured in Cardiomyocyte Maintenance Medium prior to being fixed and stained for the markers Sarcomeric Alpha Actinin and Cardiac Troponin. The cells were counterstained using DAPI to allow visualization of nuclei.

Expression of Troponin T, atrial natriuretic peptide (ANP) and atrial myosin light chain 2 (MLC2a) was confirmed in Axol iPSC-Derived Atrial Cardiomyocytes using immunocytochemistry. Troponin T staining (red) confirmed the presence of cardiac myocytes which are responsible for sarcomere contraction. ANP is specifically secreted by atrial myocytes upon atrial stretching and MLC2a facilitates cardiac contractility wo. DAPI counterstain.  

Characteristics of spontaneous and evoked action potentials recorded from Axol’s Human iPSC-derived Ventricular Cardiomyocytes. Spontaneous (A) and evoked (1 Hz; B) action potentials recorded by whole-cell patch clamp. (C) Average action potential parameters for spontaneous and evoked action potentials in control conditions.

Axol’s Human iPSC-derived Ventricular Cardiomyocytes express the core cardiac ion channels INa, ICa,L and IKr. (A) Representative traces of evoked action potentials recorded under control conditions (grey) and in the presence of 100 μM Lidocaine (green), 100 nM Nifedipine (blue) or 50 nM Dofetilide (red), which show expected effects on action potential amplitude and duration. B) Average effect of each compound on spontaneous action potential parameters, presented as percent of control ± SEM, N ≥ 4. Statistical significance calculated by a paired two-tailed Student’s t-test (* p<0.05, ** p<0.01, *** p<0.001).

Axol’s Human iPSC-Derived Ventricular Cardiomyocytes were treated with doxorubicin (control, 500 nM, 100 nM and 50 nM). There was a dose-dependent response at 13 h and 24 h post-treatment with doxorubicin. Arrhythmias and loss of beating amplitude were seen at lower doxorubicin concentration, whereas higher doxorubicin concentrations resulted in tachycardia and ultimately cell death. Data kindly provided by Dr J. Maynes, University of Toronto.

Na+와 K+를 block하는 Quinidine을 테스트. Axol의 Cardiomyocyte는 낮은 농도에서 triangulation의 증가를 확인

Anti Dopaminergic Drug인 Droperidol을 처리하여, 가장 낮은 농도에서 QT prolongation을 확인